Holen Sie sich die Stockscreener-App
1.04
2.97%
0.03
Handel nachbörslich:
1.06
0.02
+1.92%
Schlusskurs vom Vortag:
$1.01
Offen:
$1.04
24-Stunden-Volumen:
806.23K
Relative Volume:
1.51
Marktkapitalisierung:
$59.18M
Einnahmen:
$10.33M
Nettoeinkommen (Verlust:
$-129.77M
KGV:
-1.0401
EPS:
-0.9999
Netto-Cashflow:
$-140.33M
1W Leistung:
+10.60%
1M Leistung:
-7.14%
6M Leistung:
-49.27%
1J Leistung:
-5.45%
1-Tages-Spanne:
$1.025
$1.08
1-Wochen-Bereich:
$0.9601
$1.08
52-Wochen-Spanne:
$0.8824
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Firmenname
Tscan Therapeutics Inc
Sektor
Branche
Telefon
857-399-9500
Adresse
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.04 | 57.47M | 10.33M | -129.77M | -140.33M | -0.9999 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-16 | Eingeleitet | BTIG Research | Buy |
| 2024-05-13 | Eingeleitet | Needham | Buy |
| 2023-06-22 | Eingeleitet | Wedbush | Outperform |
Tscan Therapeutics Inc Aktie (TCRX) Neueste Nachrichten
Market Recap: Will TScan Therapeutics Inc stock benefit from M A2026 Technical Overview & Low Risk Profit Maximizing Plans - baoquankhu1.vn
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation - TipRanks
TScan Therapeutics announces resignation of vice president of finance - Investing.com UK
TScan Therapeutics announces resignation of vice president of finance By Investing.com - Investing.com Australia
TScan Therapeutics (TCRX) CFO adds principal accounting officer role after VP finance resignation - Stock Titan
TCRX Technical Analysis & Stock Price Forecast - Intellectia AI
TCRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Strong analyst sentiment on TScan Therapeutics (TCRX) amid ongoing momentum in cell therapy space - MSN
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space - Yahoo Finance
Earnings Risk: Will TScan Therapeutics Inc stock benefit from M A2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aug Catalysts: Will TScan Therapeutics Inc outperform its industry peersQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Retail Trends: What is the implied volatility of TScan Therapeutics Inc2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
How does TScan Therapeutics Inc score in quality rankings2026 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Risk Check: Will TScan Therapeutics Inc outperform its industry peersMarket Sentiment Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Geopolitics Watch: Is TScan Therapeutics Inc. stock risky to hold now2026 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
TCRXTscan Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00 - Defense World
TCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
What are the risks of holding TScan Therapeutics Inc2025 Trade Ideas & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Stop Loss: What is the next catalyst for TScan Therapeutics Inc2025 Market WrapUp & Weekly Return Optimization Alerts - baoquankhu1.vn
HC Wainwright Issues Positive Outlook for TCRX Earnings - MarketBeat
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright - MarketBeat
Tscan Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
TCRX: Pivotal trial for relapse-preventing T-cell therapy launches in Q2, targeting major market expansion - TradingView
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
TScan Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027. - Bitget
TScan Therapeutics 10-K: $10.3M Collaboration Revenue, $(129.8)M Net Loss - TradingView
TScan Therapeutics (NASDAQ: TCRX) advances TSC-101 and reshapes pipeline - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) details 2025 loss, growth and cash runway - Stock Titan
Earnings Breakdown: TScan Therapeutics Q4 - Benzinga
TScan Therapeutics Q4 net loss widens - TradingView
BRIEF-TScan Therapeutics Q4 Net Income USD -22.977 Million - TradingView
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
Needham Reaffirms Their Buy Rating on TScan Therapeutics (TCRX) - The Globe and Mail
TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial - marketscreener.com
TScan Therapeutics Completes Enrollment in Cohort C of - GlobeNewswire
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
TScan Therapeutics to Present at TD Cowen 46th Annual Health Care Conference on March 4, 2026 - Quiver Quantitative
TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
Is TScan Therapeutics Inc. stock a good dividend stockWeekly Stock Report & Risk Controlled Daily Plans - mfd.ru
TScan Therapeutics (NASDAQ:TCRX) Trading Up 4.6%Here's What Happened - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Finanzdaten der Tscan Therapeutics Inc-Aktie (TCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tscan Therapeutics Inc-Aktie (TCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
| Lynx1 Capital Management LP | 10% Owner |
May 19 '25 |
Buy |
1.20 |
1,388,794 |
1,666,553 |
6,746,141 |
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):